07 Jan 2022
The National Institute for Health and Care Excellence (NICE) has rejected olaparib as a routine treatment for hormone-relapsed metastatic prostate cancer, due to high costs.
BSPED Research and Innovation Award 2024 now open
03 May 2024
Nurse and Allied Health Professionals Award 2024 – applications now open
03 May 2024
Committee opportunity: Clinical Standards Officer
03 May 2024
Updated: UK Paediatric Endocrine Standards
03 May 2024
BSPED and RCPCH statement on puberty blockers for central precocious puberty
03 May 2024